Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health announced a 10-year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar adaptive radiation therapy platform.

The agreement builds on a partnership dating to the late 1980s when University of Wisconsin-Madison Professor Thomas Mackie and his team invented technology that became Accuray's TomoTherapy System. That system integrated helical 3D image-guidance with intensity-modulated radiation therapy.

The collaboration will support clinical research, education and training, and the development of adaptive therapies for cancer care, according to the company's press release.

"This Master Research Agreement formalizes and expands our longstanding relationship with the University of Wisconsin–Madison and grounds our innovations in real-world clinical practice and impactful patient care," said Steve La Neve, President and CEO of Accuray.

Zachary Morris, professor and chair of human oncology at the university, said the agreement will accelerate translating research innovation into technologies for patients through academic-industry collaboration to advance personalized radiotherapy treatments.

The University of Wisconsin School of Medicine and Public Health ranked 10th among public medical schools for National Institutes of Health funding in federal fiscal year 2025, according to the Blue Ridge Institute for Medical Research.

Accuray is headquartered in Madison, Wisconsin, and develops radiation therapy solutions for oncology and neuro-radiosurgery applications.